Table 1. Clinicopathological details by miR-210 expression.
| Low miR-210 (n=91) | High miR-210 (n=92) | P | |
|---|---|---|---|
| Treatment | |||
| RT | 52 (57%) | 45 (49%) | 0.33 |
| RT+CON | 39 (43%) | 47 (51%) | |
| Gender | |||
| Male | 76 (84%) | 70 (76%) | 0.29 |
| Female | 15 (16%) | 22 (24%) | |
| Age (years) | 75 (53–88) | 74 (51–87) | 0.94 |
| Tumour stage | |||
| T1 | 12 (13%) | 6 (6%) | 0.48 |
| T2 | 60 (66%) | 63 (69%) | |
| T3 | 16 (18%) | 19 (21%) | |
| T4 | 3 (3%) | 4 (4%) | |
| TURBT | |||
| Complete | 39 (43%) | 39 (43%) | 0.92 |
| Partial | 27 (30%) | 27 (30%) | |
| Biopsy | 23 (25%) | 20 (22%) | |
| No data | 2 (2%) | 6 (6%) | |
| % Tumour | 75 (10–100) | 80 (10–90) | 0.03 |
| Necrosis | |||
| Present | 38 (42%) | 54 | 0.02 |
| Absent | 52 (57%) | 38 | |
| No data | 1 (1%) | 0 | |
| Concurrent pTis | |||
| Present | 32 (35%) | 18 (20%) | 0.03 |
| Absent | 59 (65%) | 74 (81%) | |
| Hb (g l−1) | 13.9 (9.3–17.2) | 13.7 (9.8–17.0) | 0.20 |
| No data | 0 (0%) | 1 (1%) | |
| HIF-1α protein | 7.5 (0–169.4) | 27.7 (0–198.8) | 0.001 |
| No data | 37 (41%) | 30 (33%) | |
| CA9 protein | 0 (0–50.9) | 4.3 (0–208.4) | 0.0004 |
| No data | 47 (52%) | 38 (41%) | |
| Glut-1 protein | 73.3 (0–283.8) | 158.8 (0–300.0) | 0.001 |
| No data | 47 (51%) | 36 (39%) | |
| 26-gene HS | 0.046 (0.001–0.13) | 0.059 (0.005–0.16) | 0.007 |
| No data | 37 (41%) | 35 (38%) |
Abbreviations: CA9=carbonic anhydrase 9; CON=carbogen and nicotinamide; Glut-1=glucose transporter-1; Hb=haemoglobin; HS=hypoxia score; pTis=carcinoma in situ; TURBT=transurethral resection of the bladder tumour.
Data are represented by n (%) or median (range).